QLT at neutral by Merrill

QLT Inc. received a neutral rating from Merrill Lynch analyst Hari Sambasivam after third-quarter results were below estimates and Visudyne sales of $75.1 million. On a positive note, Eligard sales were strong for the second consecutive quarter since the relaunch in the United States, at $34.0 million versus Merrill's $22.5 million estimate. Shares of the Vancouver, B.C.-based biopharmaceutical company were up 2 cents, or 0.24%, at $8.26. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.